Thera-SAbDab

LEXATUMUMAB

>   Structural Summary
TherapeuticLexatumumab
TargetTNFRSF10B
Heavy ChainEVQLVQSGGGVERPGGSLRLSCAASGFTFDDYGMSWVRQAPGKGLEWVSGINWNGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDLWGKGTTVTVSS
Light ChainSSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSRDSSGNHVVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure4od2 [Fvs: BA]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Lexatumumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.93%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
lexatumumab E V Q L V Q S G G G V E R P G G S L R L S C A A S G F T F D D Y G M S W V R Q A P G K G L E W V S G I N W N G G S T G Y A D S V K G R V T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C A K I L G A G R G W Y F D L W G K G T T V T V S S
4od2 E V Q L V Q S G G G V E R P G G S L R L S C A A S G F T F D D Y A M S W V R Q A P G K G L E W V S G I N W Q G G S T G Y A D S V K G R V T I S R D N A K N S L Y L Q M N S L R A E D T A V Y Y C A K I L G A G R G W Y F D Y W G K G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 95A 95B 96 97 98 99 100 101 102 103 104 105 106 107
lexatumumab S S E L T Q D P A V S V A L G Q T V R I T C Q G D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y G K N N R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C N S R D S S G N H V V F G G G T K L T V L
4od2 - S E L T Q D P A V S V A L G Q T V R I T C S G D S L R S Y Y A S W Y Q Q K P G Q A P V L V I Y G A N N R P S G I P D R F S G S S S G N T A S L T I T G A Q A E D E A D Y Y C N S A D S S G N H V V F G G G T K L T V L
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-I
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2006
INN Year Recommended2007
Companies InvolvedCambridge Antibody Technology, Human Genome Sciences
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]